The First Take: A tale of two CEOs - Valeant gets its CEO back, while GlaxoSmithKline is rumoured to be lining up a new one

FirstWord editors Matthew Dennis and Simon King discuss Michael Pearson's return as CEO of Valeant and suggestions that GlaxoSmithKline are looking to identify Andrew Witty's successor

See also ViewPoints: Valeant's credibility takes another hit and ViewPoints: Witty's wager – should GlaxoSmithKline split as prominent investor suggests?

To read more The First Take articles, click here.